Skip to main content
Top
Published in: BMC Health Services Research 1/2004

Open Access 01-12-2004 | Research article

Assessing the impact of heart failure specialist services on patient populations

Authors: Georgios Lyratzopoulos, Gary A Cook, Patrick McElduff, Daniel Havely, Richard Edwards, Richard F Heller

Published in: BMC Health Services Research | Issue 1/2004

Login to get access

Abstract

Background

The assessment of the impact of healthcare interventions may help commissioners of healthcare services to make optimal decisions. This can be particularly the case if the impact assessment relates to specific patient populations and uses timely local data. We examined the potential impact on readmissions and mortality of specialist heart failure services capable of delivering treatments such as b-blockers and Nurse-Led Educational Intervention (N-LEI).

Methods

Statistical modelling of prevented or postponed events among previously hospitalised patients, using estimates of: treatment uptake and contraindications (based on local audit data); treatment effectiveness and intolerance (based on literature); and annual number of hospitalization per patient and annual risk of death (based on routine data).

Results

Optimal treatment uptake among eligible but untreated patients would over one year prevent or postpone 11% of all expected readmissions and 18% of all expected deaths for spironolactone, 13% of all expected readmisisons and 22% of all expected deaths for b-blockers (carvedilol) and 20% of all expected readmissions and an uncertain number of deaths for N-LEI. Optimal combined treatment uptake for all three interventions during one year among all eligible but untreated patients would prevent or postpone 37% of all expected readmissions and a minimum of 36% of all expected deaths.

Conclusion

In a population of previously hospitalised patients with low previous uptake of b-blockers and no uptake of N-LEI, optimal combined uptake of interventions through specialist heart failure services can potentially help prevent or postpone approximately four times as many readmissions and a minimum of twice as many deaths compared with simply optimising uptake of spironolactone (not necessarily requiring specialist services). Examination of the impact of different heart failure interventions can inform rational planning of relevant healthcare services.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cowie MR, Wood DA, Coats AJS, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC: Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000, 83: 505-510. 10.1136/heart.83.5.505.CrossRefPubMedPubMedCentral Cowie MR, Wood DA, Coats AJS, Thompson SG, Suresh V, Poole-Wilson PA, Sutton GC: Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000, 83: 505-510. 10.1136/heart.83.5.505.CrossRefPubMedPubMedCentral
2.
go back to reference Stewart S, McIntyre K, Hole DJ, Capewell S, McMurray JJV: More "malignant" than cancer? Five -year survival following a first admission for heart failure. Eur J Heart Failure. 2001, 3 (3): 315-322. 10.1016/S1388-9842(00)00141-0.CrossRef Stewart S, McIntyre K, Hole DJ, Capewell S, McMurray JJV: More "malignant" than cancer? Five -year survival following a first admission for heart failure. Eur J Heart Failure. 2001, 3 (3): 315-322. 10.1016/S1388-9842(00)00141-0.CrossRef
4.
go back to reference Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE: The epidemiology of heart failure. Eur Heart J. 1997, 18: 208-225.CrossRefPubMed Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE: The epidemiology of heart failure. Eur Heart J. 1997, 18: 208-225.CrossRefPubMed
5.
go back to reference Blue L, Lang E, McMurray JJV, Davie AP, McDonagh TA, Murdoch DR, Petrie MC, Connoly E, Norrie J, Round CE, Ford I, Morrison CE: Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001, 323: 715-718. 10.1136/bmj.323.7315.715.CrossRefPubMedPubMedCentral Blue L, Lang E, McMurray JJV, Davie AP, McDonagh TA, Murdoch DR, Petrie MC, Connoly E, Norrie J, Round CE, Ford I, Morrison CE: Randomised controlled trial of specialist nurse intervention in heart failure. BMJ. 2001, 323: 715-718. 10.1136/bmj.323.7315.715.CrossRefPubMedPubMedCentral
6.
go back to reference Cline CMJ, Israelsson BYA, Willehnheimer RB, Broms K, Erhardt LR: Cost-effective management programme for heart failure reduces hospitalisation. Heart. 1998, 80: 442-4466.CrossRefPubMedPubMedCentral Cline CMJ, Israelsson BYA, Willehnheimer RB, Broms K, Erhardt LR: Cost-effective management programme for heart failure reduces hospitalisation. Heart. 1998, 80: 442-4466.CrossRefPubMedPubMedCentral
7.
go back to reference Michalsen A, Konig G, Thimme W: Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998, 80: 437-441.CrossRefPubMedPubMedCentral Michalsen A, Konig G, Thimme W: Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998, 80: 437-441.CrossRefPubMedPubMedCentral
8.
go back to reference Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJV: The current cost of heart failure to the National Health Service in the UK. Eur J Heart Failure. 2002, 4: 361-371. 10.1016/S1388-9842(01)00198-2.CrossRef Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJV: The current cost of heart failure to the National Health Service in the UK. Eur J Heart Failure. 2002, 4: 361-371. 10.1016/S1388-9842(01)00198-2.CrossRef
9.
go back to reference Brophy JM, Joseph L, Rouleau JL: B-blockers in congestive heart failure. Ann Int Med. 2001, 134: 550-560.CrossRefPubMed Brophy JM, Joseph L, Rouleau JL: B-blockers in congestive heart failure. Ann Int Med. 2001, 134: 550-560.CrossRefPubMed
10.
go back to reference Pitt B, Zanad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evalution Study investigators: The effect of spironolactone on moridity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341: 709-717. 10.1056/NEJM199909023411001.CrossRefPubMed Pitt B, Zanad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evalution Study investigators: The effect of spironolactone on moridity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341: 709-717. 10.1056/NEJM199909023411001.CrossRefPubMed
11.
go back to reference McAlister FA, Lawson FME, Teo KK, Armstrong PW: A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001, 110: 378-384. 10.1016/S0002-9343(00)00743-9.CrossRefPubMed McAlister FA, Lawson FME, Teo KK, Armstrong PW: A systematic review of randomized trials of disease management programs in heart failure. Am J Med. 2001, 110: 378-384. 10.1016/S0002-9343(00)00743-9.CrossRefPubMed
12.
go back to reference Stewart S, Horowitz JD: Home-based intervention in congestive heart failure. Long-term implications on readmission and survival. Circulation. 2002, 105: 2861-2866. 10.1161/01.CIR.0000019067.99013.67.CrossRefPubMed Stewart S, Horowitz JD: Home-based intervention in congestive heart failure. Long-term implications on readmission and survival. Circulation. 2002, 105: 2861-2866. 10.1161/01.CIR.0000019067.99013.67.CrossRefPubMed
13.
go back to reference Lowe JM, Candlish PM, Henry DA, Slodarcyk JH, Heller RF, Fletcher PJ: Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. Med J Aust. 1998, 168: 115-118.PubMed Lowe JM, Candlish PM, Henry DA, Slodarcyk JH, Heller RF, Fletcher PJ: Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. Med J Aust. 1998, 168: 115-118.PubMed
14.
go back to reference Cowie MR, McIntyre H, Panahloo Z, on behalf of the OMADA investigators: Delivering evidence-based care to patients with heart failure: results of a structured programme. Br J Cardiol. 2002, 9 (3): 171-180. Cowie MR, McIntyre H, Panahloo Z, on behalf of the OMADA investigators: Delivering evidence-based care to patients with heart failure: results of a structured programme. Br J Cardiol. 2002, 9 (3): 171-180.
16.
go back to reference Sign Secretariat, Diagnosis and Treatment of Heart failure due to Left Ventricular Systolic Dysfunction, Scottish Intercollegiate Guidelines Network, SIGN Publication number 35, Royal College of Physicians, Edinburgh, Scotland. 1999 Sign Secretariat, Diagnosis and Treatment of Heart failure due to Left Ventricular Systolic Dysfunction, Scottish Intercollegiate Guidelines Network, SIGN Publication number 35, Royal College of Physicians, Edinburgh, Scotland. 1999
17.
go back to reference Task Force for the diagnosis and treatment of chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001, 22: 1527-1560. 10.1053/euhj.2001.2783. Task Force for the diagnosis and treatment of chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001, 22: 1527-1560. 10.1053/euhj.2001.2783.
19.
go back to reference English KM, Channer KS: How patients with heart failure are managed in the United Kingdom. Eur J Heart failure. 1999, 1: 201-202. 10.1016/S1388-9842(99)00019-7.CrossRef English KM, Channer KS: How patients with heart failure are managed in the United Kingdom. Eur J Heart failure. 1999, 1: 201-202. 10.1016/S1388-9842(99)00019-7.CrossRef
20.
go back to reference Heller RF, Page J: A population perspective to evidence based medicine: "evidence for population health". J Epidemiol Community Health. 2002, 56 (1): 45-47. 10.1136/jech.56.1.45.CrossRefPubMedPubMedCentral Heller RF, Page J: A population perspective to evidence based medicine: "evidence for population health". J Epidemiol Community Health. 2002, 56 (1): 45-47. 10.1136/jech.56.1.45.CrossRefPubMedPubMedCentral
21.
go back to reference Capewell S, Morrison CE, McMurray JJ: Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1999, 81 (4): 380-386.CrossRefPubMedPubMedCentral Capewell S, Morrison CE, McMurray JJ: Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1999, 81 (4): 380-386.CrossRefPubMedPubMedCentral
22.
go back to reference Capewell S, Pell JP, Morrison C, McMurray J: Increasing the impact of cardiological treatments. How best to reduce deaths. Eur Heart J. 1999, 20: 1386-1392. 10.1053/euhj.1999.1631.CrossRefPubMed Capewell S, Pell JP, Morrison C, McMurray J: Increasing the impact of cardiological treatments. How best to reduce deaths. Eur Heart J. 1999, 20: 1386-1392. 10.1053/euhj.1999.1631.CrossRefPubMed
23.
go back to reference Attia J, Page J, Heller RF, Dobson AJ: Impact numbers in health policy decisions. J Epidemiol Community Health. 2002, 56: 600-605. 10.1136/jech.56.8.600.CrossRefPubMedPubMedCentral Attia J, Page J, Heller RF, Dobson AJ: Impact numbers in health policy decisions. J Epidemiol Community Health. 2002, 56: 600-605. 10.1136/jech.56.8.600.CrossRefPubMedPubMedCentral
24.
go back to reference Heller RF, Edwards R, McElduff P: Implementing guidelines in primary care: can population impact measures help?. BMC Public Health. 2003 Heller RF, Edwards R, McElduff P: Implementing guidelines in primary care: can population impact measures help?. BMC Public Health. 2003
25.
go back to reference Marshall T, Rouse A: Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ. 2002, 327: 1264-1270. 10.1136/bmj.327.7426.1264.CrossRef Marshall T, Rouse A: Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ. 2002, 327: 1264-1270. 10.1136/bmj.327.7426.1264.CrossRef
26.
go back to reference Critchley JA, Capewell S: Why model coronary heart disease?. Eur Heart J. 2002, 23: 110-116. 10.1053/euhj.2001.2681.CrossRefPubMed Critchley JA, Capewell S: Why model coronary heart disease?. Eur Heart J. 2002, 23: 110-116. 10.1053/euhj.2001.2681.CrossRefPubMed
27.
go back to reference Office for National Statistics: Compendium of clinical indicators, 1998–2000. HMSO, London. 2001 Office for National Statistics: Compendium of clinical indicators, 1998–2000. HMSO, London. 2001
29.
go back to reference Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003, 289 (6): 712-718. 10.1001/jama.289.6.712.CrossRefPubMed Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003, 289 (6): 712-718. 10.1001/jama.289.6.712.CrossRefPubMed
30.
go back to reference Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001, 344 (22): 1651-1658. 10.1056/NEJM200105313442201.CrossRefPubMed Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001, 344 (22): 1651-1658. 10.1056/NEJM200105313442201.CrossRefPubMed
31.
go back to reference Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002, 106 (17): 2194-2199. 10.1161/01.CIR.0000035653.72855.BF.CrossRefPubMed Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002, 106 (17): 2194-2199. 10.1161/01.CIR.0000035653.72855.BF.CrossRefPubMed
32.
go back to reference McAlister FA: Commentary: Relative treatment effects are consistent across the spectrum of underlying risks... usually. Int J Epidemiology. 2002, 31: 76-77. 10.1093/ije/31.1.76.CrossRef McAlister FA: Commentary: Relative treatment effects are consistent across the spectrum of underlying risks... usually. Int J Epidemiology. 2002, 31: 76-77. 10.1093/ije/31.1.76.CrossRef
33.
go back to reference Furukawa TA, Guyatt GH, Griffith LE: Can we individualize the "number needed to treat"? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002, 31: 72-78. 10.1093/ije/31.1.72.CrossRefPubMed Furukawa TA, Guyatt GH, Griffith LE: Can we individualize the "number needed to treat"? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002, 31: 72-78. 10.1093/ije/31.1.72.CrossRefPubMed
34.
go back to reference Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003, 326: 1407-1408. 10.1136/bmj.326.7404.1407.CrossRef Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003, 326: 1407-1408. 10.1136/bmj.326.7404.1407.CrossRef
35.
go back to reference Mant J, Hicks N: Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ. 1995, 311: 793-796.CrossRefPubMedPubMedCentral Mant J, Hicks N: Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ. 1995, 311: 793-796.CrossRefPubMedPubMedCentral
36.
go back to reference Hanlon P, Beck S, Robertson G, Henderson M, McQuillan R, Capewell S, Dorward A: Coping with the inexorable rise in medical admissions: evaluating a radical reorganisation of acute medical care in a Scottish district general hospital. Health Bull (Edinb). 1997, 55 (3): 176-184. Hanlon P, Beck S, Robertson G, Henderson M, McQuillan R, Capewell S, Dorward A: Coping with the inexorable rise in medical admissions: evaluating a radical reorganisation of acute medical care in a Scottish district general hospital. Health Bull (Edinb). 1997, 55 (3): 176-184.
37.
go back to reference Benbassat J, Taragin M: Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med. 2000, 16 (8): 1074-1081. 10.1001/archinte.160.8.1074.CrossRef Benbassat J, Taragin M: Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med. 2000, 16 (8): 1074-1081. 10.1001/archinte.160.8.1074.CrossRef
39.
go back to reference Unal B, Critchley JA, Capewell S: Missing, mediocre or merely obsolete? An evaluation of UK data sources for coronary heart disease. J Epidemiol Community Health. 2003, 57: 530-535. 10.1136/jech.57.7.530.CrossRefPubMedPubMedCentral Unal B, Critchley JA, Capewell S: Missing, mediocre or merely obsolete? An evaluation of UK data sources for coronary heart disease. J Epidemiol Community Health. 2003, 57: 530-535. 10.1136/jech.57.7.530.CrossRefPubMedPubMedCentral
40.
go back to reference Harley K, Jones C: Quality of Scottish morbidity record (SMR) data. Health Bull (Edinb). 1996, 54: 410-417. Harley K, Jones C: Quality of Scottish morbidity record (SMR) data. Health Bull (Edinb). 1996, 54: 410-417.
41.
go back to reference McMurray J, McDonagh T, Morrison CE, Dargie HJ: Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J. 1993, 14: 1158-1162.CrossRefPubMed McMurray J, McDonagh T, Morrison CE, Dargie HJ: Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J. 1993, 14: 1158-1162.CrossRefPubMed
42.
go back to reference Stewart S, Demers C, Murdoch DR, McIntyre K, MacLeod ME, Kendrick S, Capewell S, McMurray JJ: Substantial between-hospital variation in outcome following first emergency admission for heart failure. Eur Heart J. 2002, 23: 650-657. 10.1053/euhj.2001.2890.CrossRefPubMed Stewart S, Demers C, Murdoch DR, McIntyre K, MacLeod ME, Kendrick S, Capewell S, McMurray JJ: Substantial between-hospital variation in outcome following first emergency admission for heart failure. Eur Heart J. 2002, 23: 650-657. 10.1053/euhj.2001.2890.CrossRefPubMed
43.
go back to reference Department of Health: Coronary heart disease national service frameworks. HMSO. 2000 Department of Health: Coronary heart disease national service frameworks. HMSO. 2000
45.
go back to reference Task Force for the diagnosis and treatment of chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001, 22: 1527-1260. 10.1053/euhj.2001.2783. Task Force for the diagnosis and treatment of chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001, 22: 1527-1260. 10.1053/euhj.2001.2783.
46.
go back to reference Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J, IMPROVEMENT of Heart failure Programme Committees and Investigators: Management of heart failure in primary care (the IMPROVEMENT of Heart failure Programme): an international survey. Lancet. 2002, 360: 1631-1639. 10.1016/S0140-6736(02)11601-1.CrossRefPubMed Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J, IMPROVEMENT of Heart failure Programme Committees and Investigators: Management of heart failure in primary care (the IMPROVEMENT of Heart failure Programme): an international survey. Lancet. 2002, 360: 1631-1639. 10.1016/S0140-6736(02)11601-1.CrossRefPubMed
47.
go back to reference Heller RF, Fisher JD, D'Este CA, Lim L, Dobson AJ, Porter R: Death and readmission in the year after hospital admission with cardiovascular disease: the Hunter Area Heart and Stroke Register. Med J Austr. 2000, 172: 261-265. Heller RF, Fisher JD, D'Este CA, Lim L, Dobson AJ, Porter R: Death and readmission in the year after hospital admission with cardiovascular disease: the Hunter Area Heart and Stroke Register. Med J Austr. 2000, 172: 261-265.
Metadata
Title
Assessing the impact of heart failure specialist services on patient populations
Authors
Georgios Lyratzopoulos
Gary A Cook
Patrick McElduff
Daniel Havely
Richard Edwards
Richard F Heller
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2004
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-4-10

Other articles of this Issue 1/2004

BMC Health Services Research 1/2004 Go to the issue